Course Title: Complement Inhibition: New insights into the management of gMG  
Course Date and time: November 30 at 7:00pm to 8:15pm Eastern  
Chair: Dr. Zaeem Siddiqi  
Speakers: Dr. Angela Genge, Dr. Dubravka Dodig

Course Description: Applying the science of complement inhibition to improve clinical outcomes in refractory AChR+ gMG
- The historical treatment of refractory AChR+ gMG
- Overview of the efficacy and safety data unpinning the label for eculizumab in refractory AChR+ gMG
- Clinical trial evidence: Review of the REGAIN study including recent post-hoc analyses
- Real world evidence supporting the use of eculizumab in clinical practice.
- Safety and efficacy of switching from Intravenous Immunoglobulin to eculizumab in Patients with Treatment-Refractory Myasthenia Gravis.
- New International guidance on the use of complement inhibition in the treatment of refractory gMG.
- Present 2-3 real world clinical cases looking at impact of complement inhibition in the treatment of refractory gMG.

By the end of this course participants will be able to:
- Appreciate the burden of disease that refractory AChR+ gMG have on patients, including their impact on daily living.
- Understand the role of complement in the pathophysiology of generalized myasthenia gravis (gMG).
- Discuss the role of complement inhibition in the treatment of refractory AChR+ gMG including recent real-world evidence together with Canadian patient case presentations

Audience: Neurologists with an interest in neuromuscular diseases

Learning Level: Intermediate (Practicing Physician)

Learning Format: Lecture/plenary method, Question and answer sessions

CanMEDs Roles: Medical Expert

Agenda: 3-4 polling questions will be asked during the meeting.

<table>
<thead>
<tr>
<th>Time</th>
<th>Description</th>
<th>Name of Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-7:05 pm</td>
<td>Welcome and opening remarks</td>
<td>Zaeem Siddiqi</td>
</tr>
<tr>
<td>7:05-7:20 pm</td>
<td>Refractory gMG and associated pathophysiology</td>
<td>Angela Genge</td>
</tr>
<tr>
<td>7:20-7:30 pm</td>
<td>Canadian patient case introductions</td>
<td>Dubravka Dodig</td>
</tr>
<tr>
<td>7:30-7:50 pm</td>
<td>Complement inhibition and treatment landscape in gMG</td>
<td>Angela Genge</td>
</tr>
<tr>
<td>7:50-8:00 pm</td>
<td>Canadian patient case outcomes</td>
<td>Dubravka Dodig</td>
</tr>
<tr>
<td>8:00-8:15 pm</td>
<td>Panel discussion and Q &amp; A</td>
<td>Zaeem Siddiqi</td>
</tr>
<tr>
<td></td>
<td>Evaluation &amp; Wrap Up</td>
<td>Zaeem Siddiqi</td>
</tr>
</tbody>
</table>

This Webinar is an unaccredited group learning approved by the Canadian Neurological Sciences Federation. The program was developed by the Canadian Neurological Sciences Federation and Faculty and was planned to achieve scientific integrity, objectivity and balance. This Webinar was supported by Alexion Pharma Canada who provided an unrestricted grant and in-kind support.